Tucatinib Combination Induces Positive Intracranial Responses in HER2-Positive Breast Cancer Brain Metastases

Tucatinib in combination with trastuzumab and capecitabine yielded significant intracranial responses in patients with previously treated HER2-positive metastatic breast cancer and brain metastases.

Source: CancerNetwork - June 4, 2020 Category: Cancer & Oncology Authors: Lisa Astor Source Type: news